Fulgent Total Assets vs Total Current Assets Analysis
FLGT Stock | USD 22.32 0.13 0.59% |
Fulgent Genetics financial indicator trend analysis is much more than just examining Fulgent Genetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulgent Genetics is a good investment. Please check the relationship between Fulgent Genetics Total Assets and its Total Current Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.
Total Assets vs Total Current Assets
Total Assets vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulgent Genetics Total Assets account and Total Current Assets. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Fulgent Genetics' Total Assets and Total Current Assets is 0.89. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Fulgent Genetics, assuming nothing else is changed. The correlation between historical values of Fulgent Genetics' Total Assets and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Fulgent Genetics are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Assets i.e., Fulgent Genetics' Total Assets and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.89 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Assets
Total assets refers to the total amount of Fulgent Genetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Fulgent Genetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Fulgent Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Discontinued Operations is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 93.4 M in 2024, whereas Tax Provision is likely to drop slightly above 2.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 777.1M | 366.9M | 96.6M | 179.1M | Total Revenue | 992.6M | 619.0M | 289.2M | 266.7M |
Fulgent Genetics fundamental ratios Correlations
Click cells to compare fundamentals
Fulgent Genetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fulgent Genetics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 88.8M | 700.5M | 1.3B | 1.4B | 1.3B | 1.3B | |
Other Current Liab | 3.6M | 62.7M | 36.7M | 58.4M | 49.1M | 51.6M | |
Total Current Liabilities | 6.0M | 131.1M | 112.8M | 116.2M | 73.0M | 49.4M | |
Total Stockholder Equity | 82.8M | 569.4M | 1.2B | 1.3B | 1.1B | 1.2B | |
Net Tangible Assets | 82.8M | 569.4M | 1.2B | 973.0M | 1.1B | 1.2B | |
Property Plant And Equipment Net | 6.0M | 40.2M | 62.3M | 81.4M | 94.3M | 99.0M | |
Net Debt | (9.3M) | (71.6M) | (143.6M) | (58.9M) | (82.6M) | (78.4M) | |
Retained Earnings | (63.4M) | 150.9M | 657.6M | 801M | 633.2M | 664.8M | |
Accounts Payable | 1.6M | 26.5M | 20.5M | 23.1M | 15.4M | 10.3M | |
Cash | 12.0M | 87.4M | 164.9M | 79.5M | 97.5M | 50.9M | |
Non Current Assets Total | 12.0M | 84.7M | 204.3M | 480.4M | 765.3M | 803.5M | |
Non Currrent Assets Other | (36.8M) | (88.0M) | 142.0M | (287.4M) | 32.0M | 33.6M | |
Other Assets | 251K | 44.5M | 912.6M | 26.6M | 1.0 | 0.95 | |
Cash And Short Term Investments | 70.2M | 431.9M | 935.5M | 852.9M | 424.2M | 312.5M | |
Net Receivables | 6.6M | 183.9M | 138.9M | 52.7M | 57.4M | 50.2M | |
Common Stock Shares Outstanding | 18.7M | 24.1M | 31.0M | 31.0M | 29.8M | 23.5M | |
Liabilities And Stockholders Equity | 88.8M | 700.5M | 1.3B | 1.4B | 1.3B | 1.3B | |
Inventory | 277K | 16.5M | 12.2M | 4.3M | 5.8M | 4.4M | |
Other Current Assets | 277K | (16.5M) | (12.2M) | 22.2M | 26.2M | 27.6M | |
Other Stockholder Equity | 146.1M | 418.1M | 487.1M | 477.4M | 481.3M | 258.2M | |
Total Liab | 6.0M | 131.1M | 112.8M | 116.2M | 139.8M | 146.8M | |
Property Plant And Equipment Gross | 8.6M | 41.0M | 81.9M | 124.6M | 135.1M | 141.9M | |
Total Current Assets | 76.8M | 615.7M | 1.1B | 905.6M | 507.8M | 365.6M | |
Accumulated Other Comprehensive Income | 146K | 438K | (759K) | (20.9M) | 1.2M | 1.3M | |
Property Plant Equipment | 8.6M | 40.2M | 62.3M | 98.9M | 113.8M | 119.4M | |
Retained Earnings Total Equity | (63.0M) | (63.4M) | 150.9M | 657.6M | 756.2M | 794.0M | |
Short Term Investments | 58.3M | 344.4M | 770.7M | 773.4M | 326.7M | 326.9M | |
Non Current Liabilities Total | 2.3M | 959K | 7.5M | 28.1M | 66.8M | 70.1M | |
Capital Surpluse | 114.2M | 146.1M | 418.1M | 501.9M | 577.2M | 606.1M | |
Long Term Investments | 42.8M | 132.5M | 507.0M | 339.0M | 444.0M | 466.2M | |
Non Current Liabilities Other | 2.3M | 959K | 7.5M | 28.1M | 11.0M | 6.8M | |
Net Invested Capital | 82.8M | 584.4M | 1.2B | 1.3B | 1.1B | 688.3M | |
Net Working Capital | 33.4M | 393.5M | 961.6M | 539.8M | 434.8M | 381.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.56) | Revenue Per Share 9.635 | Quarterly Revenue Growth (0.03) | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.